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ABSTRACT
Objective: To investigate whether there is an
association between use of ACE inhibitors (ACEI) and
angiotensin receptor blockers (ARB) and risk of acute
kidney injury (AKI).
Study design: We conducted a new-user cohort
study of the rate of AKI among users of common
antihypertensives.
Setting: UK primary care practices contributing to the
Clinical Practice Research Datalink (CPRD) eligible for
linkage to hospital records data from the Hospital
Episode Statistics (HES) database between April 1997
and March 2014.
Participants: New users of antihypertensives: ACEI/
ARB, β-blockers, calcium channel blockers and thiazide
diuretics.
Outcomes: The outcome was first episode of AKI. We
estimated incidence rate ratio (RR) for AKI during time
exposed to ACEI/ARB compared to time unexposed,
adjusting for age, sex, comorbidities, use of other
antihypertensive drugs and calendar period using
Poisson regression. Covariates were time updated.
Results: Among 570 445 participants, 303 761 were
prescribed ACEI/ARB with a mean follow-up of
4.1 years. The adjusted RR of AKI during time exposed
to ACEI/ARB compared to time unexposed was 1.12
(95% CI 1.07 to 1.17). This relative risk varied
depending on absolute risk of AKI, with lower or no
increased relative risk from the drugs among
those at greatest absolute risk. For example, among
people with stage 4 chronic kidney disease (who had
6.69 (95% CI 5.57 to 8.03) times higher rate of AKI
compared to those without chronic kidney disease),
the adjusted RR of AKI during time exposed to
ACEI/ARB compared to time unexposed was
0.66 (95% CI 0.44 to 0.97) in contrast to 1.17 (95%
CI 1.09 to 1.25) among people without chronic kidney
disease.
Conclusions: Treatment with ACEI/ARB is associated
with only a small increase in AKI risk while individual
patient characteristics are much more strongly
associated with the rate of AKI. The degree of
increased risk varies between patient groups.
INTRODUCTION
Acute kidney injury (AKI) is a sudden
decline in renal function, affecting up to
20% of people admitted to hospital, and is
strongly associated with increased mortality
and longer duration of hospital stay.1
Prevention and better management of
patients with AKI is the focus of national pro-
grammes2 and global campaigns.3
It is strongly believed that ACE inhibitors
(ACEI) and angiotensin receptor blockers
(ARB) are associated with development of
AKI, particularly during acute illness. ACEI/
Strengths and limitations of this study
▪ This is the largest study of this topic to date; it
examines an inclusive population-based cohort
and reflects routine clinical use of these
medications.
▪ By comparing ACE inhibitors/angiotensin receptor
blockers use to use of other antihypertensives,
we were able to reduce confounding by indication
compared to previous case–control studies.
▪ We were able to clearly define and adjust for cov-
ariates, including renal function, prior to starting
the medication. The time-updated analysis
reduced residual confounding, while restriction
to only incident users reduced adherence bias.
▪ However, there are a number of important limita-
tions. Our assessment of drug exposure was
based on prescriptions so we cannot be certain
that people prescribed the drug were taking the
medication.
▪ We did not have inpatient biochemical data so
could only use International Classification of
Diseases 10th revision (ICD-10) coding to define
acute kidney injury (AKI). Therefore, we have
captured only a proportion of the cases defined
by current biochemical definitions of AKI,
although this includes a greater proportion of
more severe cases.
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ARBs cause preferential vasodilation of the kidney’s
efferent arterioles (the small blood vessels that leave the
kidney glomeruli) thereby reducing kidney ﬁltration
pressure for a given systemic blood pressure. During
severe hypovolaemia or hypotension (eg, due to volume
depletion in acute illness), this reduction of efferent vas-
cular tone leads to reduced glomerular ﬁltration and
potentially AKI.4 While biologically plausible, evidence
to support the belief that ACEI/ARB use causes AKI is
limited. The incidence of AKI in randomised controlled
trials of ACEI and ARB compared to placebo is poorly
described due to variable deﬁnitions or absent reporting
of kidney-related adverse events.5 Previous observational
studies have compared the risk of AKI in patients using
ACEI/ARB alone to the risks among ACEI/ARB users
also taking diuretics and/or non-steroidal anti-
inﬂammatory drugs (NSAIDs),6–8 or with ACEI/ARB
alone under speciﬁc circumstances.9–11 However, the
risk of AKI in patients taking ACEI or ARB alone com-
pared to other comparator drugs has not been exam-
ined in a population cohort using individual patient
data. In contrast, high-quality evidence from randomised
trials of increased risk of AKI associated with dual pre-
scription of ACEI and ARB12 13 compared to single
agent therapy has led to a restriction on the use of these
drugs in combination.14
Despite this limited evidence, there is a growing con-
sensus that ACEI/ARB should be withheld during acute
illness.15 16 Guidelines for patients to self-manage medi-
cations linked to AKI during these situations, known as
‘sick day rules’, are being widely introduced.17 Therefore,
we aimed to investigate the association between AKI and
the use of ACEI/ARB in a large population-based cohort
study of people starting treatment with commonly used
antihypertensive drugs (ACEI/ARB, β blockers, calcium
channel blockers, thiazide diuretics). We chose to
compare new users of different classes of antihyperten-
sive drugs to reduce confounding by indication.
METHODS
Study design and setting
We undertook a cohort study using the UK Clinical
Practice Research Datalink (CPRD) and linked hospital
record data from the Hospital Episode Statistics (HES)
database. CPRD is a database of routinely collected
primary care electronic health record data from 7% of
the UK population.18 Included patients are largely repre-
sentative of the UK population.18–20 HES records cover
all admissions for NHS funded patients treated in either
English NHS trusts or by independent providers.21
Fifty-eight per cent of general practices included in
CPRD are linked to HES data (representing 75% of
English practices).18 We used only fully linked data from
CPRD and HES to ensure that all participants had com-
plete data regarding the exposure (antihypertensive pre-
scribing in primary care) and the outcome (hospital
admission with AKI). The study period was from 1 April
1997 to 31 March 2014, the latest date for which there is
HES data linkage to CPRD. This study was approved by
the LSHTM Research Ethics Committee (reference
6536) and by the CPRD independent scientiﬁc advisory
committee (ISAC protocol number: 14-208).
Participants, exposures and outcomes
To minimise confounding by indication, rather than
comparing ACEI/ARB users to otherwise healthy indivi-
duals, we identiﬁed a cohort of new users of drugs that
were prescribed for similar indications to ACEI/ARB.
We developed a cohort of all HES-linked CPRD patients
aged 18 years or older who were new users of antihyper-
tensive drugs (ACEI/ARB, β blockers, calcium channel
blockers or thiazide diuretics) during the study period.
The primary exposure was use of ACEI/ARB, and other
drugs were treated as potential confounders. To ensure
that we had reliable measures of drug use and baseline
covariates, we required that all participants had at least
1 year of continuous registration in CPRD before the
ﬁrst recorded antihypertensive drug prescription. We
calculated the length of each prescription using the
quantity of medication prescribed and the daily dose
recorded, excluding patients for whom dosing informa-
tion was inadequate to obtain a robust duration of
exposure. Exposure to medications was assumed to start
on the date of the prescription. We identiﬁed continu-
ous courses of therapy by allowing for a 60-day gap
between the end date of one prescription and the start
of the next consecutive prescription (to allow for stock
piling of medications).
Drug exposure status was time updated based on con-
tinuous courses of therapy. We deﬁned exposure status
using four time-varying, binary indicator variables to
indicate exposure to each antihypertensive, with expos-
ure status ‘switching on’ when an individual was pre-
scribed a drug and ‘off’ when their prescription ended
(example scenarios illustrating the assignment of indica-
tor variables are included in online supplementary text
S1 and ﬁgure S1). This allowed us to maximise the avail-
able follow-up time, control for exposure to other anti-
hypertensives, allowed drug combinations to be
investigated through interaction terms and more closely
modelled real life prescribing patterns.
Follow-up started at ﬁrst prescription for the ﬁrst of
any of the antihypertensive drugs and ended at either
occurrence of the outcome or the earliest of (1) end of
ﬁnal prescription; (2) death; (3) left GP practice; (4)
last data collection or (5) diagnosis of end-stage renal
disease (ESRD) (see online supplementary text S2). We
excluded patients with ESRD prior to cohort entry.
We deﬁned the outcome as the ﬁrst episode of AKI
identiﬁed within 28 days of the start of a hospital admis-
sion identiﬁed using ICD-10 morbidity coding in HES
(see online supplementary table S1), to capture cases of
AKI that were present at hospital admission but may
have not been immediately diagnosed, without exclud-
ing cases that resulted in a prolonged admission. The
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actual number of AKI cases is likely to be higher than
that captured by ICD-10 coding as less severe cases may
not result in hospitalisation or may not be coded in hos-
pital records.
Covariates
Owing to the complex and overlapping potential risk
factors for AKI, we used a directed acyclic graph
(DAG) approach to visualise our a priori assumptions
about the potential biological mechanisms between
exposure and outcome and to guide adjustment for
confounding in sequentially adjusted regression models
(see online supplementary ﬁgure S2).22 By asking
researchers to produce an illustration of the a priori
paths between exposure, outcome and potential con-
founders, causal diagrams offer a “starting point for
identifying variables that must be measured and con-
trolled [for] to obtain unconfounded effect esti-
mates”.23 We identiﬁed potential confounders based on
clinical knowledge and previous research investigating
predictors of AKI.6 7 9 10
We adjusted for baseline chronic kidney disease
(CKD) stage, established by calculating estimated glom-
erular ﬁltration rate (eGFR) using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equa-
tion.24 We used serum creatinine results recorded in the
12 months before ﬁrst prescription to calculate eGFR,
using either the highest eGFR from the most recent two
serum creatinine results, separated by a minimum of
3 months or, if only one creatinine result was available,
the single most recent serum creatinine recorded prior
to ﬁrst prescription. Serum creatinine measurements
were not routinely isotope-dilution mass spectrometry
(IDMS)-standardised until 2013. We therefore assumed
that all creatinine results were unstandardised and multi-
plied results with a correction factor of 0.95 before cal-
culating eGFR without regard to ethnicity.25 To avoid
selection bias, we included an absent CKD category for
those with no recorded serum creatinine result in the
12 months prior to ﬁrst antihypertensive prescription.
Other chronic comorbidities included as confounders
were as follows: diabetes mellitus, hypertension, cardiac
failure, cardiac arrhythmia and ischaemic heart disease,
identiﬁed from CPRD and HES data. In regression ana-
lyses, these comorbidities were recorded as time-varying
variables representing ‘ever diagnosed,’ whose status
changed with the ﬁrst recorded code for each speciﬁc
condition. Age group was entered as a time-updating
variable. We adjusted for time-varying exposure to loop
and potassium-sparing diuretics in addition to antihyper-
tensive drugs.7
We used existing morbidity code lists and algorithms
for ethnicity,19 smoking status, alcohol intake, body mass
index (BMI)20 and chronic comorbidities.26–30
Socioeconomic status was deﬁned using quintiles of
index of multiple deprivation scores for 2004.
We included calendar period as a covariate to adjust
for the many changes in clinical, diagnostic and
administrative practices over the study period that may
inﬂuence the measurement of baseline renal function
and number of reported AKI cases.
Statistical analysis
When variables (such as drug exposure, age and
comorbidities) did not remain constant over time, we
deﬁned them as time-varying variables. We did this by
splitting the data for each study subject into several
observations, each observation started on the date of a
change in that subject’s status (eg, the prescription of a
new drug, the diagnosis of a new comorbidity or a
change in age). In the main analysis, we classiﬁed expos-
ure status using a time-varying binary indicator variable
for person-time prescribed an ACEI/ARB. Rather than
comparing a group of individual patients prescribed a
particular class of drugs to another group prescribed a
different class, we compared person-time taking one
drug to person-time taking another. To avoid immortal
time bias, we excluded all time when patients were not
taking any antihypertensive drugs. We estimated RRs
associated with time exposed to antihypertensive treat-
ment including an ACEI/ARB, compared to time
exposed to antihypertensive treatment that did not
include an ACEI/ARB, adjusting for potential confoun-
ders using Poisson regression. We used robust SEs to
account for clustering by general practice. We initially
adjusted for age and sex only and then ﬁtted an adjusted
model including DAG-informed time-varying confoun-
ders (age, sex, chronic comorbidities, other antihyper-
tensive drugs, loop and potassium-sparing diuretics and
calendar period). Further adjustments were for
smoking, alcohol, BMI and socioeconomic status. All
data management and analyses were performed using
Stata V.13 (StataCorp, Texas, USA). We have made code
lists for all covariates available in online repository at:
https://clinicalcodes.rss.mhs.man.ac.uk/.31
Sensitivity analyses
To determine the impact of including individuals with
unknown baseline renal function, we repeated the main
analysis in the subgroup of the cohort with known base-
line renal function. Next, we repeated the main analysis
in new entrants to the cohort, who had ethnicity
recorded in CPRD or HES, after 2006 when recording
of ethnicity was rewarded in primary care leading to
improvements in CPRD data completeness.19 We
included ethnicity in the equation used to calculate
eGFR and as a covariate in the analysis. Finally, we tested
the robustness of the deﬁnition of AKI in a range of sen-
sitivity analyses including limiting the deﬁning ICD-10
code to just N17, which has a high positive predictive
value for AKI.32
Additional analyses
We conducted three additional analyses. First, we investi-
gated the impact of including interaction terms between
treatment with loop diuretics and, separately, potassium-
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sparing diuretics and ACEI/ARB—as concurrent use of
ACEI/ARB and diuretics has been linked to increased
risk of AKI.6 7 In our second additional analysis, renal
function was time updated to examine how the relation-
ship between AKI and ACEI/ARB exposure was related
to renal function at the time that AKI occurred, rather
than at entry to the cohort. To minimise misclassiﬁca-
tion of CKD stage by renal function measured during an
AKI episode, we excluded all measurements of kidney
function that occurred within 1 week of an admission
with AKI.33 Finally, we investigated whether there was
any difference in the rate of AKI during time exposed to
ACEI compared to ARB and during combination
therapy.12 13
RESULTS
Study population and baseline characteristics
Of 1 373 441 individuals aged 18 years or older with a
new prescription for an ACEI/ARB, β blocker, calcium
channel blocker or thiazide diuretic identiﬁed in the
CPRD between April 1997 and March 2014, 570 445
were included in the ﬁnal cohort (ﬁgure 1). Of these,
303 763 (53%) were prescribed an ACEI/ARB during
follow-up. Total follow-up time for the whole cohort was
over 2.3 million person years and 56% (1 320 001/2 345
098) of that was time exposed to ACEI/ARB. Follow-up
ended a mean of 4.1 years (SD 4.1) after ﬁrst antihyper-
tensive drug prescription. A total of 14 907 people devel-
oped AKI. The characteristics of the overall cohort and
the cohort during time exposed to antihypertensive
treatment regimens that either included or excluded an
ACEI/ARB are presented in table 1. Those exposed to
ACEI/ARB were more likely to be men with cardiac
comorbidities and to have had renal function measured
prior to starting an antihypertensive. Fifty-three per cent
of time exposed to antihypertensive treatment including
an ACEI/ARB was between 2009 and 2014 compared to
38% of time exposed to antihypertensive treatment
excluding an ACEI/ARB.
Association of ACEI or ARB prescription with rate of AKI
The association between covariates including age and
comorbidities is shown in online supplementary table
S2. In the fully adjusted model, age above 70 years, base-
line CKD stage 3B and above, loop diuretic treatment
and cardiac failure were all associated with a greater
than doubling of AKI risk. Over the whole study period,
the age and sex adjusted incidence RR for ﬁrst AKI com-
paring time exposed to antihypertensive treatment
including an ACEI/ARB to that excluding an ACEI/
ARB was 1.69 (95% CI 1.63 to 1.76), which fell to 1.12
(95% CI 1.07 to 1.17) after full adjustment (see online
supplementary table S2). Further adjustment for lifestyle
covariates and socioeconomic status made marginal dif-
ference to all results (see online supplementary table
S3). Among subgroups with the highest absolute rates of
AKI such as those with cardiac failure and CKD stage 4,
there was no measurable association (or an apparent
protective effect) of AKI with ACEI/ARB treatment
(ﬁgure 2).
Sensitivity analyses
Inclusion of only those with known baseline CKD stage,
adjustment for ethnicity and varying the way that AKI
was deﬁned from ICD-10 coding made minimal differ-
ences to the RR for AKI comparing time exposed to
antihypertensive treatment including an ACEI/ARB to
that excluding an ACEI/ARB (see online supplementary
table S3).
Interaction between diuretics and ACEI/ARB treatment
There was an interaction between loop diuretics and
ACEI/ARB treatment; there was no apparent increase in
risk of AKI associated with ACEI/ARB exposure during
periods of treatment with loop diuretic. Among people
exposed to loop diuretics, the RR for AKI during time
exposed to treatment including an ACEI/ARB com-
pared to that excluding an ACEI/ARB was 0.98 (95% CI
0.91 to 1.24), whereas among those not requiring loop
diuretics the RR was 1.18 (95% CI 1.13 to 1.24)
(p<0.001). Absolute rates of AKI stratiﬁed by ACEI/ARB
treatment and comorbidity, modelled with inclusion of
the interaction term, highlight the higher rates of AKI
among people taking loop diuretics within each stratum
(see online supplementary table S4 and ﬁgure S4).
There was no evidence for an interaction between
potassium-sparing diuretics and ACEI/ARB treatment
(RR for AKI among those prescribed potassium-sparing
Figure 1 Flow diagram showing the creation of the cohort
and reasons for exclusion. ACEI/ARB, ACE inhibitors inhibitor/
angiotensin receptor blocker; BB, β blocker; CCB, calcium
channel blocker; CPRD, Clinical Practice Research Datalink;
HES, Hospital Episode Statistics; ESRD, end-stage renal
disease.
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diuretics during time exposed to ACEI/ARB compared
to time unexposed 1.09 (95% CI 0.96 to 1.24), whereas
among those not requiring potassium-sparing diuretics,
the RR was 1.12 (95% CI 1.08 to 1.17: p=0.667)).
Impact of change in renal function on rate of AKI
When renal function was time updated, the RR for AKI
during time exposed to antihypertensive treatment
including and excluding an ACEI/ARB was attenuated
Table 1 Person-time under follow-up broken down by patient-level characteristics and ACEI/ARB exposure status
Whole cohort
Cohort during time exposed to
antihypertensive treatment
including an ACEI/ARB
Cohort during time exposed
to antihypertensive treatment
excluding an ACEI/ARB
Total person years at risk 2 345 098 1 320 001* 1 025 097*
Median person years at risk (IQR) 2.8 (0.4–7) 3.6 (1.1–6.9) 0.8 (0.2–3.4)
Range of person years at risk 0.0–17.0 0.0–17.0 0.0–17.0
AKI
Number of events 14 907 10 157 4750
Sex
Female 1 152 897 (49.2) 577 957 (43.8) 574 940 (56.1)
Age (years)
18–44 151 515 (6.5) 73 332 (5.6) 78 183 (7.6)
45–54 350 170 (14.9) 211 576 (16.0) 138 593 (13.5)
55–59 274 706 (11.7) 161 826 (12.3) 112 881 (11.0)
60–64 324 416 (13.8) 188 097 (14.2) 136 319 (13.3)
65–69 326 139 (13.9) 184 344 (14.0) 141 795 (13.8)
70–74 308 156 (13.1) 171 103 (13.0) 137 053 (13.4)
75–84 467 754 (19.9) 255 577 (19.4) 212 178 (20.7)
85+ 142 242 (6.1) 74 146 (5.6) 68 096 (6.6)
CKD stage (eGFR in mL/min/1.73 m2)
No CKD (eGFR≥60) 934 070 (39.8) 580 871 (44.0) 353 199 (34.5)
CKD stage 3a (eGFR 45–59) 113 238 (4.8) 68 074 (5.2) 45 163 (4.4)
CKD stage 3b (eGFR 30–44) 18 435 (0.8) 10 873 (0.8) 7562 (0.7)
CKD stage 4 (eGFR 15–29) 1926 (0.1) 1036 (0.1) 890 (0.1)
Baseline CKD status absent 1 277 429 (54.5) 659 145 (49.9) 618 283 (60.3)
Comorbidities
Diabetes mellitus 504 053 (21.5) 371 423 (28.1) 132 630 (12.9)
Ischaemic heart disease 735 949 (31.4) 437 433 (33.1) 298 516 (29.1)
Cardiac failure 152 904 (6.5) 116 449 (8.8) 36 456 (3.6)
Arrhythmia 281 141 (12.0) 156 555 (11.9) 124 586 (12.2)
Hypertension 2 036 050 (86.8) 1 194 641 (90.5) 841 409 (82.1)
Other antihypertensive drugs
β blockers 764 584 (32.6) 289 190 (21.9) 475 394 (46.4)
Calcium channel blockers 732 628 (31.2) 331 429 (25.1) 401 199 (39.1)
Thiazides 742 535 (31.7) 328 679 (24.9) 413 855 (40.4)
Non-thiazide diuretic drugs
Loop diuretics 155 911 (6.6) 118 565 (9.0) 37 346 (3.6)
Potassium-sparing diuretics 42 047 (1.8) 25 015 (1.9) 17 033 (1.7)
Ethnicity
White 982 377 (41.9) 569 946 (43.2) 412 431 (40.2)
South Asian 26 933 (1.1) 17 647 (1.3) 9286 (0.9)
Black 148 301 (0.6) 6723 (0.5) 8108 (0.8)
Other 7832 (0.3) 4792 (0.4) 3041 (0.3)
Mixed heritage 2553 (0.1) 1490 (0.1) 1063 (0.1)
Not stated or missing 1 310 572 (55.9) 719 403 (54.5) 591 169 (57.7)
Calendar period
1997–2000 93 628 (4.0) 26 446 (2.0) 67 182 (6.6)
2001–2004 418 412 (17.8) 170 465 (12.9) 247 947 (24.2)
2005–2008 742 558 (31.7) 422 466 (32.0) 320 092 (31.2)
2009–2011 646 221 (27.6) 416 685 (31.6) 229 535 (22.4)
2012–2014 444 280 (18.9) 283 938 (21.5) 160 342 (15.6)
Data are person years unless otherwise stated. Numbers in brackets are column percentages unless otherwise specified.
*Note that numbers exposed to antihypertensive treatment regimens including an ACEI/ARB and excluding an ACEI/ARB do not total the
whole cohort number as individuals may be included in both columns.
ACEI/ARB, ACE inhibitors inhibitor/angiotensin receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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to 1.02 (95% CI 0.98 to 1.07) (see online supplementary
table S2). Among people who developed AKI, the
median number of days between last measurement of
eGFR and admission with the AKI episode was 116 days
(IQR 44–258 days).
Rate of AKI in users of ACEI compared to ARB, or both
combined
Compared to time not exposed to either drug, exposure
to an ACEI was associated with an adjusted RR for AKI of
1.14 (95% CI 1.09 to 1.19), while exposure to an ARB was
associated with a RR of 1.06 (95% CI 1.00 to 1.12). Dual
therapy with an ACEI and an ARB was associated with
nearly twice the rate of AKI compared to time unexposed
to either drug (RR 1.83 95% CI 1.53 to 2.17).
DISCUSSION
Among antihypertensive users, we found a 12% (95% CI
1.07 to 1.17) increase in the rate of AKI during time
exposed to ACEI/ARB compared to time unexposed
(after adjustment for comorbidities, additional drug
exposure and calendar period). However, this relative
risk varied markedly among different subgroups and was
highest among those with the lowest absolute risk of
AKI. There was no evidence of increased AKI risk for
ACEI/ARB users among those at greatest absolute risk
of AKI (eg, those with comorbidities or those also pre-
scribed loop diuretics). Adjustment for most recent
renal function further attenuated the risk of AKI due to
ACEI/ARB exposure. We have shown that treatment
with ACEI is associated with a similar magnitude of risk
of AKI as ARB, but there is a near doubling of risk of
AKI during time exposed to ACEI and ARB. In addition
to examining the effect of antihypertensives on AKI risk,
we have calculated absolute rates of AKI in a general
population cohort and the impact of important
comorbidities and age on these rates.
To illustrate our results, it is useful to consider the
number of cases of AKI associated with ACEI/ARB use
Figure 2 Modelled rates* of AKI (during the calendar period 2012–2014) per 1000 person years at risk for AKI during time
exposed to antihypertensive treatment including ACEI/ARB compared to time exposed to antihypertensive treatment excluding
ACEI/ARB, stratified by characteristics and comorbidities. *Absolute rates (unless otherwise stated) are for men, aged 75–84,
with CKD stage 3a, and no comorbidities—chosen as a large, clinically important, high-risk group. **Adjusted using Poisson
regression for age, sex, chronic comorbidities (CKD, hypertension, diabetes mellitus, cardiac failure, ischaemic heart disease and
arrhythmia), time exposed to other antihypertensive drugs (β blockers, calcium channel blockers and thiazides), time exposed to
loop and potassium-sparing diuretics and calendar period. AKI, acute kidney injury; ACEI/ARB, ACE inhibitors inhibitor/
angiotensin receptor blocker; pyar, Person years at risk; CKD, chronic kidney disease; ACEI/ARB exposed, antihypertensive
treatment including ACEI/ARB; ACEI/ARB unexposed, antihypertensive treatment excluding ACEI/ARB; IRR, incidence rate ratio.
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within different subgroups. Assuming that differences in
AKI rates were directly attributable to ACEI/ARB expos-
ure, in a low risk group—such as those with normal
renal function—despite a 17% increase in relative risk of
AKI during ACEI/ARB treatment, for 1000 people,
removal of the drug would reduce the number of AKI
cases from 10 to 8 per year. In contrast, in a group at
high absolute risk of AKI—such as those with cardiac
failure treated with loop diuretics—exposure to ACEI/
ARB has minimal impact. Among 1000 such people,
there are 76 cases of AKI in those treated with ACEI/
ARB and 78 cases among those not treated.
Strengths and limitations
This is the largest study of this topic to date; it examines
an inclusive population-based cohort from primary care
and reﬂects routine clinical use of these medications. By
comparing ACEI/ARB use to other antihypertensives,
we were able to reduce confounding by indication com-
pared to previous case–control studies. We were able to
clearly deﬁne and adjust for covariates including renal
function prior to starting the medication. The time-
updated analysis reduced residual confounding, while
restriction to only incident users reduced adherence
bias.
However, there are a number of important limitations.
Our assessment of drug exposure was based on prescrip-
tions so we cannot be certain that people prescribed the
drug were taking the medication; importantly we were
unable to take into account any temporary discontinu-
ation in medication use during acute illness or hospital-
isation. We did not have inpatient biochemical data so
could only use ICD-10 coding to deﬁne AKI. Therefore,
we have captured only a proportion of the cases deﬁned
by current biochemical deﬁnitions of AKI (although this
includes a greater proportion of more severe cases34 35)
and we were not able to grade the severity of AKI. We
examined ﬁrst episode of AKI only. We cannot be
certain that AKI was present at the time of hospital
admission or developed while in hospital; although we
have conducted several sensitivity analyses to investigate
the impact of varying our AKI deﬁnition in an attempt
to address this. It is possible that there is bias in classiﬁ-
cation of the outcome. For example, due to awareness of
an association, hospital staff may be more likely to recog-
nise and code AKI in patients taking ACEI/ARB.
Alternately, patients taking these drugs may have more
frequent monitoring of renal function and therefore be
more likely to have AKI detected. However, these
sources of bias would lead to an overestimate of the asso-
ciation between ACEI/ARB and AKI. We did not
examine the additional effects of NSAIDs because these
have been examined in previous studies.6–8 There is
limited and selective data on proteinuria from primary
care records so we were not able to adjust for this poten-
tially important covariate. Finally, this study is limited to
NHS patients in England, which may restrict its
generalisability.
Comparison to other studies
Previous high-quality evidence regarding the association
between ACEI/ARB and AKI is scarce. Estimates of the
increase in AKI risk associated with use of ACEI/ARB
from randomised trials are limited.5 Many commonly
cited observational studies are cross-sectional or address
the risk of AKI in relation to speciﬁc diseases or inter-
ventions.8–10 Two recent nested case–control studies
using UK primary care data reported only relative risks
for AKI among users of NSAIDS in addition to ACEI/
ARB and diuretics.6 7 Only one population-based study
has examined the relative risk of AKI among ACEI/ARB
users compared to non-users. This study, despite limited
data quality, found similar results to our own with a fully
adjusted OR of 1.11 (95% CI 1.02 to 1.20) comparing
those prescribed and not prescribed ACEI/ARB.36
However, strong evidence does exist in relation to the
risks of AKI associated with combined ACEI and ARB
therapy. Here, recent clinical trials using this regime
have reported HRs for renal adverse events ranging
from 1.20 (95% CI 0.96 to 1.50) to 2.19 (95% CI 1.13 to
4.22), compared to single agent treatment alone.12 13
Our results, showing a near doubling of rate for AKI
with dual blockade, are similar to these ﬁndings and
strongly support the validity of our study.
Finally, similar to other recent studies, we show that
the rate of AKI detected by ICD-10 coding has increased
markedly over the time period of this study. This is well
documented and likely to be multifactorial, attributable
to better hospital coding, increased recognition of AKI
and possibly a true increase in incidence.37
Possible explanations and implications for clinicians and
policymakers
Although surprising, we believe that this study has pro-
vided the most accurate estimates of the strength of the
association between ACEI/ARB use and AKI to date.
One alternate explanation for the small effect size is that
we have compared time exposed to ACEI/ARB to other
antihypertensives, with no untreated comparison group.
While this design reduces confounding by indication, it
is possible that all antihypertensives increase AKI risk
during acute illness. In addition, among those at the
highest absolute risk of AKI (eg, those with additional
comorbidities), we found rates of AKI for ACEI/ARB
users were lower than those for non-users. The probable
explanation for these ﬁndings is that, in patients with
multiple comorbidities that are indications for ACEI/
ARB treatment, not being treated with ACEI or ARB is a
marker of unmeasured poor health status or frailty. For
example, an individual may have stopped ACEI/ARB
treatment when they became unwell, perhaps due to
worsening renal function, and the reason for stopping
ACEI/ARB places them at higher risk of AKI during sub-
sequent follow-up. This is likely to have attenuated the
estimate of the strength of association between ACEI/
ARB and AKI over the whole study population, although
the proportion of patients with multiple comorbidities is
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small. Finally, our results do not exclude that AKI
among users of ACEI/ARB is more severe compared to
users of other antihypertensives. However, even when
the AKI deﬁnition was restricted to code positions repre-
senting the primary diagnosis, ACEI/ARB treatment was
only associated with a 21% (95% CI 11% to 33%)
increase in AKI rate.
We have also shown that patients taking loop diuretics
have higher rates of AKI than similar patients not pre-
scribed the drugs. This may be causal, due to salt and
water depletion during acute illness, or additional loop
diuretic treatment may be a marker of severity of
comorbidities. We anticipated that pharmacological inter-
action between loop diuretics and ACEI/ARB would be
associated with an increased risk of AKI compared to
treatment with loop diuretics alone but we have shown
the converse. Again, this is likely to be explained by con-
founding by underlying health status where the most
severely unwell patients at highest risk of AKI are not
treated with diuretics and ACEI/ARB. Finally, we have
shown that when adjusted for most recent renal function,
there was no measurable association between ACEI/ARB
use and AKI. The ﬁndings of this analysis have to be con-
sidered in light of possible misclassiﬁcation of CKD stage
by renal function measured during an AKI episode,
although we excluded all measurements of kidney func-
tion that occurred before of an admission with AKI.
Treatment with ACEI and ARB are widely believed to
be risk factors for AKI, particularly during acute illness.
This underlies the ‘sick-day rules’ recommendation for
patients to stop taking these drugs when they become
acutely unwell with symptoms of gastroenteritis or
fever.17 This study was not designed to examine the
effect of temporary cessation of these drugs on the
development of AKI. However, we have demonstrated
that patient comorbidities are much stronger risk factors
for the development of AKI than these drugs and that
there is no measurable effect of the drugs among those
at highest risk of AKI. This reinforces the importance of
assessing overall risk of AKI in planning potential inter-
ventions aimed at lowering hospital admissions with AKI.
Patients with multiple risk factors but not taking ACEI/
ARB may be those who would beneﬁt most from close
review of ﬂuid balance and intensive monitoring during
acute illness, but they may be overlooked if the clinical
focus is on drug cessation.
CONCLUSIONS
Our results show that treatment with ACEI/ARB appears
to be associated with only a small increase in AKI risk
while patient characteristics (such as age and comorbid-
ities) are much more strongly associated with the rate of
AKI. While people may beneﬁt from optimised medi-
cines management during acute illness, our results
suggest that these interventions should be targeted at
individuals at highest risk of AKI rather than focussing
on users of ACEI/ARB.
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